Prevalence of Financial Conflicts of Interest Among Authors of Clinical Guidelines Related to High-Revenue Medications
The presence of financial conflicts of interest in clinical practice guidelines (CPGs) may affect the objectivity of these documents. Although the National Academy of Medicine has created policies to limit industry influence on the a Represents the total number of author and chairs, who are US-based physicians with payments from pharmaceutical companies marketing 1 of the top 10 medications in clinical practice guidelines, considering both payments declared in the guideline and additional payments identified through CMS-OP. b The NAM standards assessed are (1) written disclosure of all potential financial conflicts of interest, (2) appointing committee chairs with no financial conflicts of interest, and (3) limiting guideline authors with financial conflicts of interest to less than 50% of the panel. c Guideline chairs and co-chairs and more than 50% of guideline development group should be free of conflicts of interest relevant to the subject matter of the of the project for at least 1 year prior to the guideline development to 1 year after completion. d Guideline chairs and co-chairs and more than 50% of guideline development group members should be free of commercial, noncommercial, intellectual, institutional, and patient or public activities pertinent to the potential scope of the clinical practice guideline. No timeline provided. e Guideline chairs and co-chairs and more than 50% of guideline development group members should be free of personal (ie, direct payment to the individual) financial conflicts that may result in financial benefit prior to appointment onto the guideline panel for 1 year prior to the guideline development. f Guideline chairs and co-chairs and more than 50% of members should be free of conflicts of interest, defined as any relationship that has the potential to bias, or that might be reasonably perceived by others to bias, an individual's judgment, for 3 years prior to guideline development. g Not stated.
h Guideline chairs and co-chairs and more than 50% of guideline development group members should not receive industry funding as an employee, consultant, or principal investigator specific to the activities of the committee or groups. Those with industry relationships should recuse themselves from voting on any decision. We searched for authors on the CMS-OP website to identify payments not declared in the CPG. We only included US-based physicians in our study sample, defined as authors with CMS-OP profiles. We limited our search to the CPG publication year and the year prior. We assessed each guideline for adherence to 3 National Academy of Medicine standards: written disclosure of all potential financial conflicts of interest; appointing committee chairs with no financial conflicts of interest; and limiting guideline authors with financial conflicts of interest to less than 50% of the panel. Results | We identified 18 CPGs that provided recommendations for 10 high-revenue medications, written by 160 authors who were US-based physicians (Table) . A total of 79 authors (49.4%) declared receipt of a payment in the CPG or supplemental materials, with 50 (31.3%) declaring receipt of payments from companies marketing 1 of the 10 high-revenue medications recommended in the CPG. An additional 41 authors (25.6%) were found to have received but not disclosed receipt of payments from companies marketing 1 of the 10 high-revenue medications recommended within the CPGs. Thus, in total, 91 authors (56.9%) were found to have financial conflicts of interest (Figure) .
Among all authors, the median value of undeclared payments from companies marketing 1 of the 10 high-revenue medications recommended in the CPGs was $522 (interquartile range, $0-$40 444) from 2 companies (interquartile range, 0-4). With respect to adherence to National Academy of Medicine standards, no CPGs had complete written disclosure of all potential financial conflicts of interest, 4 appointed chairs without financial conflicts of interest, and 8 limited authors with financial conflicts of interest to less than 50% of the panel.
Discussion | Authors of CPGs related to high-revenue medications have a substantial number of undeclared payments from industry, including those from pharmaceutical companies that market the medications recommended in those CPGs. In addition, most guidelines fail to adhere to national standards for financial conflicts of interest in CPGs. Guidelines related to high-revenue medications may be at especially high risk of having authors with financial conflicts of interest because pharmaceutical companies expend considerable resources marketing their top products. 4 This marketing may take the form of payments to physicians, which have been shown to affect clinical decision making.
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This study is limited by potential inaccuracies in CMS-OP reporting, which are rarely corrected, 6 and lack of generalizability outside the United States. In addition, the CMS-OP website began publishing data from mid-2013. Since we collected only several months of CMS-OP data for guidelines published in 2013, we may have underestimated the financial conflicts of interest for these guidelines. Finally, we did not have access to guideline voting records and thus did not know when conflicted panel members recommended against a medication or recused themselves from voting. Editor's Note page 1715
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